Immune Conversion of Tumor Microenvironment by Oncolytic Viruses: The Protoparvovirus H-1PV Case StudyAntonio Marchini(European Commission), Jean Rommelaere(German Cancer Research Center)Frontiers in ImmunologyAugust 7, 201910.3389/fimmu.2019.01848Cited by 87SaveCiteExport RISWatch citationsRelated Papers682: Synergistic combination of valproic acid and oncolytic parvovirus H-1PV as a potential therapy against cervical and pancreatic carcinomas|European Journal of Cancer|2014|7